Raymond James: Med Tech Prices Largely Stable in 2025 After Short Upturn
Raymond James analyzed decade-long pricing data for medical technology and found that, after a period of deflation followed by modest price gains in 2023-24, reported pricing in 2025 was effectively flat once Johnson & Johnson's Stelara loss of exclusivity is removed. The firm concludes that volume growth, not price increases, remains the key reven…